Patients with type 2 diabetes can achieve cardiovascular protection from use of SGLT2 inhibitors



All type 2 diabetes patient subgroups are likely to achieve cardiovascular protection from the use of SGLT2 inhibitors, according to a large multi-study review published in the Journal of the American Heart Association.



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.